A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer-Reference-Cited by-同舟云学术

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer

Published:2013-07 Issue:7 Volume:24 Page:1777-1785
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Cohn A.L.,Tabernero J.,Maurel J.,Nowara E.,Sastre J.,Chuah B.Y.S.,Kopp M.V.,Sakaeva D.D.,Mitchell E.P.,Dubey S.,Suzuki S.,Hei Y.-J.,Galimi F.,McCaffery I.,Pan Y.,Loberg R.,Cottrell S.,Choo S.-P.

Funder

Amgen Inc

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/7/1777/13789331/mdt057.pdf

Reference42 articles.

1. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer;Cunningham;N Engl J Med,2004

2. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer;Van Cutsem;J Clin Oncol,2007

3. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer;Peeters;J Clin Oncol,2010

4. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004

5. Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC10262-VELOUR);Van Cutsem;Presented at: 13th World Congress on Gastrointestinal Cancer,2011

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma;Clinical Cancer Research;2023-07-03

2. GH and IGF1 in cancer therapy resistance;Endocrine-Related Cancer;2023-06-07

3. Pathophysiology of Gastrointestinal Tract Cancers and Therapeutic Status;Phytonutrients in the Treatment of Gastrointestinal Cancer;2023-04-27

4. Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer;Gynecologic Oncology;2023-03

5. Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy;Cells;2022-11-22